Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 10/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CPT1A | P50416 | 3/20 | 0.35 |
| ▸ | CPT2 | P23786 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4680643 | 0.93 | ENPP2 (0.39) | ENPP2CPT1ACPT2NPC1RAB9A | |
| SCHEMBL4686047 | 0.89 | CPT1A (0.37) | MAPTCPT1ACPT2 | |
| SCHEMBL4787558 | 0.89 | ALDH1A1 (0.35) | ENPP2ALDH1A1CPT1ACPT2 | |
| SCHEMBL4678379 | 0.86 | CPT1A (0.34) | MAPTCPT1ACPT2 | |
| SCHEMBL6400638 | 0.86 | HCRTR2 (0.31) | CPT1ACPT2 | |
| SCHEMBL4684410 | 0.85 | ALDH1A1 (0.37) | MC4RENPP2LMNAKMT2AMAPT | |
| SCHEMBL4680646 | 0.79 | ENPP2 (0.38) | ENPP2CPT1ACPT2 | |
| SCHEMBL6405908 | 0.75 | MAPT (0.36) | LMNAKMT2AMAPTHTTALDH1A1 | |
| SCHEMBL4686052 | 0.74 | CPT1A (0.37) | LMNAKMT2AMAPTALDH1A1CPT1A | |
| SCHEMBL4787561 | 0.74 | ALDH1A1 (0.34) | ENPP2KMT2AALDH1A1CPT1ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1437349-B9 | SUBSTITUTED ISOXAZOLES AND THE USE THEREOF AS ANTIBIOTICS | S A L V A T LAB SA (ES) | 2008-09-10 | — | — | EP | disclosed |
| EP-1437349-B1 | SUBSTITUTED ISOXAZOLES AND THE USE THEREOF AS ANTIBIOTICS | S A L V A T LAB SA (ES) | 2007-08-15 | — | — | EP | disclosed |
| US-20050014806-A1 | Substituted isoxazoles and their use as antibiotics | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2005-01-20 | — | — | US | disclosed |
| EP-1437349-A1 | SUBSTITUTED ISOXAZOLES AND THE USE THEREOF AS ANTIBIOTICS | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014806-A1 | Substituted isoxazoles and their use as antibiotics | XDH, SCO2, HAX1 | MC4R 1161/4885ENPP2 3361/4885LMNA 2423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.